妓院一钑片免看黄大片,亚洲av无码成人精品国产,亚洲AV综合色区无码专区桃色,免费A级毛片在线播放不收费

美國Covidien
Covidien(柯惠)的前身是泰科醫(yī)療(Tyco Healthcare)。
Covidien Ltd（紐約證券交易所：COV、百慕大證券交易所：COV）是全球領(lǐng)先的衛(wèi)生保健產(chǎn)品公司，其創(chuàng)建革新的醫(yī)療解決方案，通過臨床領(lǐng)導(dǎo)能力及卓越的表現(xiàn)來使病人實現(xiàn)更好的結(jié)果，并實現(xiàn)價值。Covidien制造、分銷多種業(yè)界領(lǐng)先的產(chǎn)品線，并為這些產(chǎn)品線提供服務(wù)，包括外科設(shè)備、基于能量的設(shè)備、呼吸和監(jiān)控解決方案、病人護(hù)理與安全產(chǎn)品、影像解決方案、醫(yī)藥產(chǎn)品、醫(yī)療用品。2006年，Covidien的收入達(dá)到近100億美元，在世界上的57個國家中雇有43,000名員工，其產(chǎn)品銷往130多個國家。2007年7月2號開始在紐約證券交易所和百慕大證券交易所進(jìn)行交易，這意味著公司首次成為獨立的多元化醫(yī)療保健產(chǎn)品公司。這也表示眾所周知的Tyco Healthcare業(yè)務(wù)最近從Tyco International中正獨立。

　　憑借業(yè)界領(lǐng)先的品牌名稱（包括：Autosuture、Kendall、Mallinckrodt、Nellcor、Puritan Bennett、Syneture、U.S.Surgical和Valleylab），Covidien在醫(yī)療設(shè)備、影像解決方案、醫(yī)藥產(chǎn)品、醫(yī)療用品以及零售產(chǎn)品產(chǎn)品等五大業(yè)務(wù)部門在市場上競爭。2006年，Covidien收益達(dá)到96億美元，其中三分之一以上的銷售額是在美國以外實現(xiàn)的。 Covidien在57個國家雇有43,000名員工，其產(chǎn)品銷往130多個國家。

Covidien五大業(yè)務(wù)部門的特色
　　醫(yī)療設(shè)備部（占銷售的59％）

醫(yī)療設(shè)備部是最大的業(yè)務(wù)部門，在2006年其凈銷售額達(dá)到了57億美元。
這一多樣化產(chǎn)品部門在多種醫(yī)療設(shè)備市場是全球領(lǐng)先者，其單一產(chǎn)品的銷售額不超過總銷售額的1％。
體現(xiàn)了Covidien在全球廣泛的足跡，醫(yī)療設(shè)備銷售中有54％是在美國以外實現(xiàn)的。
對于外科設(shè)備、能量設(shè)備、呼吸和監(jiān)控解決方案、病人護(hù)理和安全產(chǎn)品以及眾多革新產(chǎn)品來說，醫(yī)療設(shè)備部是最重要的部門。
　　影像解決方案部（占銷售的9％）　　

在2006年，影像解決方案產(chǎn)品的凈銷售額達(dá)90億美元。
Covidien影像解決方案部以最精確的早期疾病診斷為終極目標(biāo)，在生產(chǎn)多種形態(tài)的放射性藥劑（X-ray、MRI和核醫(yī)療）、造影劑和造影交付系統(tǒng)方面是全球領(lǐng)先者。
遵循全企業(yè)創(chuàng)新哲學(xué)，影像解決方案部將醫(yī)療影像技術(shù)從注重‘解剖和功能影像技術(shù)轉(zhuǎn)移到‘分子級影像技術(shù)’上。這種轉(zhuǎn)變可幫助臨床醫(yī)生在更早的階段進(jìn)行疾病診斷、治療和監(jiān)控。
　　醫(yī)藥產(chǎn)品部（占銷售額的13％）

2006年實現(xiàn)的凈銷售額達(dá)到12億美元，擁有多個產(chǎn)品線，從配藥醫(yī)藥品到藥物活性成分以及特制化學(xué)產(chǎn)品。
Covidien是美國第九大醫(yī)藥公司（擁有眾多配藥處方）
作為世界上控制中樞神經(jīng)類物質(zhì)的最大制造商，Covidien是病人安全與及控制中樞神經(jīng)類物質(zhì)調(diào)節(jié)方面的先驅(qū)。
Covidien也是醋氨酚以及其它多種止痛藥品的全球領(lǐng)先者
　　醫(yī)療用品部（占銷售額的10％）

在2006年凈銷售額達(dá)近10億美元，醫(yī)療用品部是病人護(hù)理材料領(lǐng)域的領(lǐng)先者。
Covidien的各種產(chǎn)品讓手術(shù)室、護(hù)理站和醫(yī)師的辦公室中擁有最高質(zhì)量的臨床材料。
產(chǎn)品線包括：傷口護(hù)理材料、醫(yī)療外科產(chǎn)品、原始設(shè)備制造商產(chǎn)品、失禁用品（歐洲）以及其它產(chǎn)品。
在核心醫(yī)療用品類中，Covidien的市場份額位居第一或第二。
　　零售產(chǎn)品部（占銷售額的9％）

在零售產(chǎn)品部門，Covidien是北美地區(qū)自有品牌成人失禁產(chǎn)品、嬰兒護(hù)理產(chǎn)品以及女性衛(wèi)生產(chǎn)品領(lǐng)域的領(lǐng)先制造商，在2006年的凈銷售額達(dá)到8億美元。
在美國20家頂級零售商中，Covidien是為17家提供自有品牌成人失禁產(chǎn)品、嬰兒護(hù)理產(chǎn)品以及女性衛(wèi)生產(chǎn)品的獨家或者多家授權(quán)供貨商。

At Covidien, we're passionate about making doctors, nurses, pharmacists and other medical professionals as effective as they can be. From Autosuture to Valleylab, from Kendall to Mallinckrodt, our industry-leading brands are known worldwide for uncompromising quality.

Through ongoing collaboration with medical professionals and organizations, we identify clinical needs and translate them into proven products and procedures. Over the years, we've pioneered a number of medical advances including contrast media, pulse oximetry, electrosurgery, surgical stapling and laparoscopic instrumentation.

Offering an extensive product line that spans medical devices, imaging solutions, pharmaceuticals and medical supplies, we serve healthcare needs in hospitals, long-term care and alternate care facilities, doctors’ offices and in the home.

International in every respect Covidien is part of the local fabric of the communities where we operate. Deriving 45% of our sales from outside the United States, Covidien's success wouldn’t be possible without the dedication of our 41,000 employees, who live in 59 countries. More than two-thirds of our colleagues work in 60 manufacturing facilities, located in 16 countries. In addition, more than 4,800 sales representatives in more than 50 countries meet our customers’ needs every day.

Strategic Initiatives, Core strengths At Covidien, we believe that supporting the lifesaving work of medical professionals and emphasizing growth are not mutually exclusive. In fact, our financial stability enables us to hold to our vision of being an essential resource to the healthcare profession and therefore to doing our part to improve patient outcomes.

With that in mind, we have outlined the following strategic initiatives:

Focus on Growth
Commitment to Innovation
Leveraging Our Global Structure
Driving Operational Excellence
Increased Portfolio Management
We're confident that we will succeed in these areas because of our core strengths:

Scale, product diversity and reach. As one of the largest global manufacturers and marketers in the healthcare industry, our scale and diversity allow us to invest wisely in infrastructure and technology and to develop lower cost sources of supply and global distribution. We offer products in a number of high growth healthcare areas, including laparoscopic surgery, electrosurgery, biosurgery, sleep therapy and pain management.
A portfolio of leading brands. Our brands are among the most well-known and respected in the healthcare field. Quality and reliability are their hallmarks.
Strong customer relationships. Our sales force develops and maintains strong relationships with clinician decision makers. We foster these relationships by providing extensive clinical education through dedicated training centers, by sponsoring fellowships and offering other continuing education programs.
Operational excellence. We have a history of developing and manufacturing high-quality products in a cost-effective manner. Throughout our organization, we are committed to Six Sigma, Design for Six Sigma, Lean Manufacturing and strategic sourcing initiatives to ensure product availability. We employ strict safety and quality controls to reduce disruption throughout the supply chain.
Our aim is to enhance growth by increasing research and development initiatives, pursuing targeted acquisition opportunities and enhancing our global infrastructure, including sales, marketing and distribution.